SG11202107317WA - Combinaton therapy with a don prodrug and an immune checkpoint inhibitor - Google Patents
Combinaton therapy with a don prodrug and an immune checkpoint inhibitorInfo
- Publication number
- SG11202107317WA SG11202107317WA SG11202107317WA SG11202107317WA SG11202107317WA SG 11202107317W A SG11202107317W A SG 11202107317WA SG 11202107317W A SG11202107317W A SG 11202107317WA SG 11202107317W A SG11202107317W A SG 11202107317WA SG 11202107317W A SG11202107317W A SG 11202107317WA
- Authority
- SG
- Singapore
- Prior art keywords
- combinaton
- therapy
- immune checkpoint
- checkpoint inhibitor
- don prodrug
- Prior art date
Links
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 title 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 title 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 title 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 title 1
- 229940002612 prodrug Drugs 0.000 title 1
- 239000000651 prodrug Substances 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962794231P | 2019-01-18 | 2019-01-18 | |
| PCT/US2020/014149 WO2020150639A1 (en) | 2019-01-18 | 2020-01-17 | Combinaton therapy with a don prodrug and an immune checkpoint inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202107317WA true SG11202107317WA (en) | 2021-08-30 |
Family
ID=71614516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202107317WA SG11202107317WA (en) | 2019-01-18 | 2020-01-17 | Combinaton therapy with a don prodrug and an immune checkpoint inhibitor |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220117938A1 (en) |
| EP (1) | EP3911310A4 (en) |
| JP (1) | JP2022518232A (en) |
| KR (1) | KR20210117303A (en) |
| CN (1) | CN113438947A (en) |
| AU (1) | AU2020208637A1 (en) |
| BR (1) | BR112021014112A2 (en) |
| CA (1) | CA3126822A1 (en) |
| EA (1) | EA202191992A1 (en) |
| IL (1) | IL284907A (en) |
| MX (1) | MX2021008546A (en) |
| SG (1) | SG11202107317WA (en) |
| WO (1) | WO2020150639A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022552168A (en) * | 2019-10-03 | 2022-12-15 | ドラセン ファーマシューティカルズ インコーポレイテッド | Frozen containing (S)-isopropyl 2-((S)-2-acetamido-3-(1H-indol-3-yl)propanamide)-6-diazo-5-oxohexanoate for intravenous administration Dry composition and its use |
| WO2022022612A1 (en) * | 2020-07-29 | 2022-02-03 | Jacobio Pharmaceuticals Co., Ltd. | Novel glutamine analogs |
| WO2022072820A1 (en) * | 2020-10-02 | 2022-04-07 | Dracen Pharmaceuticals, Inc. | Lyophilized composition comprising (s)-isopropyl 2-((s)-2- acetamido-3-(1h-indol-3-yl)propanamido)-6-diazo-5- oxohexanoate for subcutaneous administration and the use thereof |
| CN114621120B (en) * | 2020-12-10 | 2023-11-03 | 深圳先进技术研究院 | DON prodrug molecule, prodrug activating compound and prodrug activating system |
| WO2022232565A1 (en) * | 2021-04-29 | 2022-11-03 | The Johns Hopkins University | Prodrugs of 6-diazo-5-oxo-l-norleucine |
| WO2022261117A1 (en) * | 2021-06-07 | 2022-12-15 | Dracen Pharmaceuticals, Inc. | Combination therapy with a don prodrug and a tigit inhibitor |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160113925A1 (en) * | 2014-10-22 | 2016-04-28 | Emory University | Methods of treating cancer with a combination of glucose modulators and bcl-2 inhibitors |
| EP3328376A4 (en) * | 2015-07-31 | 2019-03-13 | The Johns Hopkins University | Methods and compositions for treating metabolic reprogramming disorders |
| CN112920092B (en) * | 2015-07-31 | 2024-04-26 | 约翰霍普金斯大学 | Prodrugs of glutamine analogues |
| US20180244783A1 (en) * | 2015-08-31 | 2018-08-30 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of disease |
| DK3692015T3 (en) * | 2017-10-06 | 2022-11-21 | Univ Johns Hopkins | PREVIOUSLY UNKNOWN GLUTAMINE ANTAGONISTS AND USES THEREOF |
-
2020
- 2020-01-17 SG SG11202107317WA patent/SG11202107317WA/en unknown
- 2020-01-17 BR BR112021014112-0A patent/BR112021014112A2/en unknown
- 2020-01-17 KR KR1020217026015A patent/KR20210117303A/en unknown
- 2020-01-17 JP JP2021541578A patent/JP2022518232A/en active Pending
- 2020-01-17 WO PCT/US2020/014149 patent/WO2020150639A1/en unknown
- 2020-01-17 EA EA202191992A patent/EA202191992A1/en unknown
- 2020-01-17 MX MX2021008546A patent/MX2021008546A/en unknown
- 2020-01-17 CN CN202080013742.1A patent/CN113438947A/en active Pending
- 2020-01-17 EP EP20741361.8A patent/EP3911310A4/en active Pending
- 2020-01-17 US US17/423,819 patent/US20220117938A1/en active Pending
- 2020-01-17 AU AU2020208637A patent/AU2020208637A1/en not_active Abandoned
- 2020-01-17 CA CA3126822A patent/CA3126822A1/en active Pending
-
2021
- 2021-07-18 IL IL284907A patent/IL284907A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210117303A (en) | 2021-09-28 |
| CA3126822A1 (en) | 2020-07-23 |
| EA202191992A1 (en) | 2021-12-17 |
| WO2020150639A1 (en) | 2020-07-23 |
| JP2022518232A (en) | 2022-03-14 |
| US20220117938A1 (en) | 2022-04-21 |
| AU2020208637A1 (en) | 2021-09-09 |
| MX2021008546A (en) | 2021-11-12 |
| EP3911310A1 (en) | 2021-11-24 |
| CN113438947A (en) | 2021-09-24 |
| EP3911310A4 (en) | 2022-10-12 |
| IL284907A (en) | 2021-09-30 |
| BR112021014112A2 (en) | 2021-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL284907A (en) | Combinaton therapy with a don prodrug and an immune checkpoint inhibitor | |
| IL267617A (en) | Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor | |
| ZA201900060B (en) | Combination comprising ep4 antagonist and immune checkpoint inhibitor | |
| IL283598A (en) | Radioimmunoconjugates and checkpoint inhibitor combination therapy | |
| IL256148B (en) | A cbp/catenin inhibitor and immune checkpoint inhibitor for use un treating cancer | |
| IL265274A (en) | Antibody and checkpoint inhibitor combination therapy | |
| IL261584A (en) | Combination of a cxcr4 antagonist and an immune checkpoint inhibitor | |
| IL292219A (en) | Immunomodulatory il-2 agents in combination with immune checkpoint inhibitors | |
| IL256467A (en) | A checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapy | |
| GB201913857D0 (en) | Computing circuitry | |
| SI3463436T1 (en) | A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer | |
| IL266521A (en) | Combination of a brd4 inhibitor and an antifolate for the therapy of cancer | |
| SG11202011261PA (en) | Urolithin a and derivatives thereof for use in therapy | |
| ZA201805548B (en) | Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor | |
| GB2583782B (en) | Computing circuitry | |
| ZA202202617B (en) | Treatment of cancer using a combination comprising multi-tyrosine kinase inhibitor and immune checkpoint inhibitor | |
| IL261505A (en) | Combination therapy using a liv1-adc and a chemotherapeutic | |
| EP3854224A4 (en) | Immune checkpoint inhibitor | |
| SG11202111820PA (en) | Oncolytic adenovirus and checkpoint inhibitor combination therapy | |
| IL260185A (en) | A combination therapy using reic/dkk-3 gene and a checkpoint inhibitor | |
| GB2575548B (en) | A cycle and a dock | |
| FI12534U1 (en) | Resin-coated overlay and a plywood article comprising the overlay | |
| GB201914731D0 (en) | A jig and use thereof | |
| GB2589437B (en) | Circuitry and methods | |
| IL262077A (en) | A computer game for practicing linear equations |